company background image
ARAY logo

Accuray NasdaqGS:ARAY Stock Report

Last Price

US$1.76

Market Cap

US$184.5m

7D

-0.6%

1Y

-38.7%

Updated

09 Oct, 2024

Data

Company Financials +

Accuray Incorporated

NasdaqGS:ARAY Stock Report

Market Cap: US$184.5m

ARAY Stock Overview

Designs, develops, manufactures, and sells radiosurgery and radiation therapy systems for the treatment of tumors in the United States, Canada, Latin America, Asia, Australia, New Zealand, Europe, the Middle East, India, Africa, Japan, and China.

ARAY fundamental analysis
Snowflake Score
Valuation4/6
Future Growth3/6
Past Performance0/6
Financial Health4/6
Dividends0/6

Accuray Incorporated Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Accuray
Historical stock prices
Current Share PriceUS$1.76
52 Week HighUS$3.05
52 Week LowUS$1.40
Beta1.4
11 Month Change-12.44%
3 Month Change-10.66%
1 Year Change-38.68%
33 Year Change-55.22%
5 Year Change-33.33%
Change since IPO-93.82%

Recent News & Updates

Accuray Remains A Perpetual 'Next Year Is Our Year' Story

Aug 18

Recent updates

Accuray Remains A Perpetual 'Next Year Is Our Year' Story

Aug 18

Accuray Incorporated's (NASDAQ:ARAY) 28% Dip In Price Shows Sentiment Is Matching Revenues

Aug 13
Accuray Incorporated's (NASDAQ:ARAY) 28% Dip In Price Shows Sentiment Is Matching Revenues

Lacklustre Performance Is Driving Accuray Incorporated's (NASDAQ:ARAY) 25% Price Drop

May 21
Lacklustre Performance Is Driving Accuray Incorporated's (NASDAQ:ARAY) 25% Price Drop

Analysts Have Lowered Expectations For Accuray Incorporated (NASDAQ:ARAY) After Its Latest Results

May 04
Analysts Have Lowered Expectations For Accuray Incorporated (NASDAQ:ARAY) After Its Latest Results

Are Investors Undervaluing Accuray Incorporated (NASDAQ:ARAY) By 25%?

May 03
Are Investors Undervaluing Accuray Incorporated (NASDAQ:ARAY) By 25%?

Accuray Getting Very Little Love Ahead Of A Coming Revenue Ramp

Apr 07

Is Accuray (NASDAQ:ARAY) A Risky Investment?

Feb 03
Is Accuray (NASDAQ:ARAY) A Risky Investment?

Why Investors Shouldn't Be Surprised By Accuray Incorporated's (NASDAQ:ARAY) 26% Share Price Plunge

Aug 17
Why Investors Shouldn't Be Surprised By Accuray Incorporated's (NASDAQ:ARAY) 26% Share Price Plunge

These 4 Measures Indicate That Accuray (NASDAQ:ARAY) Is Using Debt Extensively

Apr 13
These 4 Measures Indicate That Accuray (NASDAQ:ARAY) Is Using Debt Extensively

The Return Trends At Accuray (NASDAQ:ARAY) Look Promising

Mar 14
The Return Trends At Accuray (NASDAQ:ARAY) Look Promising

Accuray (NASDAQ:ARAY) Takes On Some Risk With Its Use Of Debt

Dec 01
Accuray (NASDAQ:ARAY) Takes On Some Risk With Its Use Of Debt

Accuray (NASDAQ:ARAY) Is Doing The Right Things To Multiply Its Share Price

Oct 27
Accuray (NASDAQ:ARAY) Is Doing The Right Things To Multiply Its Share Price

Accuray launches CyberKnife platform in Africa for cancer patients

Sep 30

Accuray GAAP EPS of -$0.04 beats by $0.03, revenue of $110.02M beats by $4.7M

Aug 10

Here's Why Accuray (NASDAQ:ARAY) Has A Meaningful Debt Burden

Jul 08
Here's Why Accuray (NASDAQ:ARAY) Has A Meaningful Debt Burden

Accuray (NASDAQ:ARAY) Might Have The Makings Of A Multi-Bagger

Jun 15
Accuray (NASDAQ:ARAY) Might Have The Makings Of A Multi-Bagger

Accuray: Nothing Special

May 31

Accuray Once Again Hits The Reset Button On Its Progress

Feb 09

A Look At The Fair Value Of Accuray Incorporated (NASDAQ:ARAY)

Jan 28
A Look At The Fair Value Of Accuray Incorporated (NASDAQ:ARAY)

Shareholder Returns

ARAYUS Medical EquipmentUS Market
7D-0.6%-0.7%0.6%
1Y-38.7%19.4%30.3%

Return vs Industry: ARAY underperformed the US Medical Equipment industry which returned 19.4% over the past year.

Return vs Market: ARAY underperformed the US Market which returned 30.3% over the past year.

Price Volatility

Is ARAY's price volatile compared to industry and market?
ARAY volatility
ARAY Average Weekly Movement18.5%
Medical Equipment Industry Average Movement8.6%
Market Average Movement6.4%
10% most volatile stocks in US Market15.0%
10% least volatile stocks in US Market3.2%

Stable Share Price: ARAY's share price has been volatile over the past 3 months compared to the US market.

Volatility Over Time: ARAY's weekly volatility has increased from 12% to 18% over the past year.

About the Company

FoundedEmployeesCEOWebsite
1990987Sandeep Chalkewww.accuray.com

Accuray Incorporated designs, develops, manufactures, and sells radiosurgery and radiation therapy systems for the treatment of tumors in the United States, Canada, Latin America, Asia, Australia, New Zealand, Europe, the Middle East, India, Africa, Japan, and China. It offers the CyberKnife platform, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of primary and metastatic tumors outside the brain, including tumors on or near the spine and in the breast, kidney, liver, lung, pancreas, and prostate. The company also provides the TomoTherapy platform, including the Radixact System, which allows for integrated radiation treatment planning, delivery, and data management, enabling clinicians to deliver ultra-precise treatments to approximately 50 patients per day; iDMS data management system, a fully integrated treatment planning and data management systems; and Accuray precision treatment planning system, a treatment planning and data management systems.

Accuray Incorporated Fundamentals Summary

How do Accuray's earnings and revenue compare to its market cap?
ARAY fundamental statistics
Market capUS$184.50m
Earnings (TTM)-US$15.54m
Revenue (TTM)US$446.55m

0.4x

P/S Ratio

-11.4x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
ARAY income statement (TTM)
RevenueUS$446.55m
Cost of RevenueUS$303.43m
Gross ProfitUS$143.12m
Other ExpensesUS$158.67m
Earnings-US$15.54m

Last Reported Earnings

Jun 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-0.16
Gross Margin32.05%
Net Profit Margin-3.48%
Debt/Equity Ratio381.9%

How did ARAY perform over the long term?

See historical performance and comparison